Health & Biotech
Headquartered in Auckland, New Zealand, Aroa Biosurgery is a soft-tissue regeneration company committed to unlocking regenerative healing for everybody through its patented AROA ECM™ complex wound and tissue reconstruction products.
The company was founded in 2008 by Veterinarian Surgeon Dr Brian Ward, who discovered that a tissue scaffold called the extra cellular matrix (ECM) found in the forestomach of sheep has a similar structure to human tissue and contains over 150 proteins known to be important in the healing process.
Listed on the ASX since 2020, Aroa Biosurgery has established USA operations, regulatory approval in over 50 countries and employs over 270 people in New Zealand and North America.
Over 6 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. www.aroabio.com
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Aroa looks to capitalise on growing US wound care market
Health & Biotech
Health Kick Podcast: Aroa sets sights on sales growth in FY25
Stockhead TV
WTF with ARX: Unlocking the power of regenerative healing
News
Closing Bell: Tech, Miners fuel ASX winning run; but Yancoal sinks 14pc after dividend halt
Health & Biotech
Aroa advances clinical evidence for soft tissue repair products
News
ScoPo’s Powerplays: ASX health stocks rise as ‘Pro Medicus again hit the ball out of the park’
Health & Biotech
Vital Signs Podcast: Aroa Biosurgery sets sights on positive operating cash flow in H2 FY25
Investor Guides
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
Health & Biotech
ASX Quarterly Health Wrap: Who is making progress for FDA approval?
Health & Biotech
ScoPo’s Powerplays: ASX health stocks up in ‘fairly lacklustre week’
Health & Biotech
Investors’ sneak peek at biotech’s bright future
Health & Biotech
Sheep-derived products propel Aroa’s global growth in soft tissue regeneration
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall as Sonic cuts FY24 profit guidance
Stockhead TV
Long Shortz with AROA Biosurgery: Delighted with full year results on Myriad of sales
News
Closing Bell: Sierra Nevada jumps 80pc on drilling plans; Ethereum rallies amid ETF whispers
Health & Biotech
Aroa meets guidance, aims for cashflow positivity in FY25
Health & Biotech